API | phenformin

phenformin Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Phenformin is a biguanide hypoglycemic agent with actions and uses similar to those of metformin. It activates AMP-activated protein kinase (AMPK) and inhibits mTORC1 signaling. Phenformin used for the treatment of diabetes. Phenformin was removed from the U.S. market 20 years ago because of a high incidence of lactic acidosis. Risk factors for the development of lactic acidosis include renal deficiency, hepatic disease, cardiac disease, and drug interaction such as cimetidine. Phenformin exerts potential anti-neoplastic action. ^NCATS

Chemistry

SMILES: N=C(N)NC(=N)NCCc1ccccc1
InChIKey: ICFJFFQQTFMIBG-UHFFFAOYSA-N
Mol. Mass: 205.26
ALogP: 0.24 Partition coefficient
ChEMBL Molecules:

phenformin

phenformin hydrochloride

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (1)

Diabetes Mellitus, Type 2

Experimental Indications - Clinical Trial Phases 1-4 (4)

Breast Neoplasms ()

COVID-19 (Phase 1/Phase 2)

Melanoma (Phase 1)

Ovarian Neoplasms ()

Overview

Highest Phase: Phase 2
# of Trials: 2
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue